Has Amy Krie, MD received payments from drug or device companies?

Yes. Drug and device makers reported $907,251 in general payments to Amy Krie, MD across 841 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amy Krie, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amy Krie, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amy Krie, MD

Medical Oncology · Minneapolis, MNNPI 1083648075

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $685,258 of the $907,251 with a category attached, or 75.5%. 8 manufacturers reported payments, led by AstraZeneca at 42.5% of the total. 2025 is the largest year on record at $230,928, 5.2 times the $44,630 reported in 2019. Among medical oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$907,251in general payments, 2019–2025

Across 841 payments — averaging $1078.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$386K
Daiichi Sankyo Inc.$201K
Gilead$137K
Stemline Therapeutics Inc.$93K
Novartis$87K
Immunomedics, Inc.$2K
plus $2K from 2 others

$1,563,146in research payments, 2019–2025

Across 154 payments — averaging $10,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$549K
Pfizer$421K
Gilead$297K
Merck$186K
Seagen Inc.$76K
Roche Products Limited$12K
plus $22K from 4 others

What the payments were for

Consulting fees$89,86810%
Speaking & faculty fees$685,25876%
Travel & lodging$121,70013%
Food & beverage$10,3281%
Education$980%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	314	$386,023
Daiichi Sankyo Inc.	225	$200,628
Gilead	124	$137,330
Stemline Therapeutics Inc.	85	$93,471
Novartis	90	$86,540
Immunomedics, Inc.	1	$1,750
Seagen Inc.	1	$1,375
Astrazeneca UK Limited	1	$135

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enhertu$399,498
Trodelvy$136,672
Orserdu$92,136
KISQALI$63,682
PIQRAY$50,704
DATROWAY$43,891
LYNPARZA$19,695
TUKYSA$1,375

How this compares

$907,251 in reported general payments places this provider in the 95th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$41,129

Medicare patients

201

Services billed

462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VerzenioAbemaciclib	17	$262,948
IbrancePalbociclib	16	$251,175
VeozahFezolinetant	14	$10,762
Tamoxifen Citrate	292	$10,179
Anastrozole	368	$9,413
Letrozole	306	$7,291
Exemestane	23	$5,213
Raloxifene Hcl	18	$888
Alendronate Sodium	35	$451
Dexamethasone	16	$446
Olanzapine	12	$264
Ondansetron Hcl	26	$217
Prochlorperazine Maleate	21	$175
Venlafaxine Hcl ErVenlafaxine Hcl	11	$92

Paid to pharmacies, not to this prescriber.

Other medical oncology in Minneapolis

Emmanuel AntonarakisMinneapolis$260K
Charles RyanMinneapolis$99K
Dean GesmeMinneapolis$92K
Robert KratzkeMinneapolis$79K
Evidio Domingo MusibayMinneapolis$38K
Emil LouMinneapolis$11K
Keith SkubitzMinneapolis$5K
Alexandra RezazadehMinneapolis$3K
Matthew NwaneriMinneapolis$3K
Amit MahipalRochester$746K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →